Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

The Trump administration’s negotiation with Novo Nordisk A/S that slashes 71% off the list price of its blockbusters Ozempic ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its ...

Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) ...

The US government said Tuesday it negotiated a 71% discount off of the list price of Novo Nordisk A/S’s blockbuster drugs ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...